Dr. Mary J. Janatpour from Dynavax Technologies | Oncotarget (VIDEO)
Caption
Low-dose cyclophosphamide decreases Tregs. Additional impacted biological activities have been described, such as:
- increased interferon production,
- induction of immunogenic cell death,
- increases in effector T cells, and
- increases in functional NK cells,
...likely to be complementary to SD-101 activity by virtue of modulation of the TME. By administering SD-101 locally, rather than systemically, the researchers demonstrate that localized SD-101 injection combined with systemically administered low-dose cyclophosphamide confers an anti-tumor response at non-injected sites.
Credit
www.oncotarget.com
Usage Restrictions
ccby
License
Licensed content